drugset
drugset / Trial / NCT00829777

Safety Study of Intravenous 6β-Naltrexol (AIKO-150) in Opioid-Dependent Subjects

NCT00829777 ↗

Phase 1 Completed 8 enrolled California Pacific Medical Center Research Institute
RandomizedSingle-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of intravenous 6β-Naltrexol administered to opiate dependent subjects

Timeline

Start
2009-03
Primary completion
2009-09
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Background Naloxone Small molecule 0.05 mg Intravenous
Background Naloxone Small molecule 0.15 mg Intravenous
Background Naloxone Small molecule 0.5 mg Intravenous
Background Lactulose Other / unclassified 10 g Oral
Background Naloxone Small molecule 0.1 mg Intravenous

Indications

opiate dependence